Gold prices slip lower; consolidating after recent gains
Charles E. Sheedy, a ten percent owner of Nuo Therapeutics, Inc. (NASDAQ:AURX), purchased 133,333 shares of common stock on July 30, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The purchase comes as the stock shows strong momentum, with InvestingPro data showing a 10% gain over the past week and a remarkable 444% return over the past year.
The shares were bought at a price of $1.50, totaling approximately $199,999. Following the transaction, Sheedy directly owns 11,570,833 shares of Nuo Therapeutics. The filing also indicates that Sheedy indirectly owns 3,365 shares held in separate trusts for the benefit of his children. With the company’s next earnings report due on August 11 and revenue growth exceeding 106% in the last twelve months, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. Subscribers can access 8 additional key insights about AURX on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.